Asthma | Unmet Need | Severe Asthma | US/EU | 2023

Several effective anti-inflammatory agents and bronchodilators are available for controlling mild or moderate asthma. However, despite the availability of long-acting muscarinic antagonists (LAMAs) (e.g., Boehringer Ingelheim’s Spiriva), long-acting beta2 agonist (LABA)/LAMA/inhaled corticosteroid (ICS) fixed-dose combinations (FDCs) (e.g., GlaxoSmithKline (GSK)’s Trelegy, Chiesi’s Trimbow), and novel biologics (e.g., AstraZeneca’s Fasenra, Teva’s Cinqair / Cinqaero, Sanofi / Regeneron’s Dupixent, GSK’s Nucala), there is still a need for effective therapies for severe disease, especially for patients whose symptoms are not adequately controlled with current therapies or who depend on frequent SABA and/or oral corticosteroid use to experience relief. This Unmet Need report provides quantitative insights into key treatment drivers and goals and the current level of unmet need in severe asthma, based on the perceptions of U.S. and European physicians. We analyze the commercial opportunities and how emerging therapies can capitalize on these opportunities.

QUESTIONS ANSWERED

• What are the drivers and goals in the treatment of severe asthma?
• Which drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
• How do current therapies perform on key treatment drivers and goals for severe asthma?
• What are the prevailing areas of unmet need and opportunity in severe asthma?
• What trade-offs across different clinical attributes and price are acceptable to U.S. and European physicians for a hypothetical new drug for severe asthma?

PRODUCT DESCRIPTION

Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP Simulator.

Markets covered: United States, France, Germany, United Kingdom

Primary research: Survey of 30 U.S. pulmonologists, 32 U.S. allergists, and 32 European pulmonologists fielded in December 2022.

Key companies: Amgen, AstraZeneca, Chiesi, GlaxoSmithKline, Novartis, Regeneron, Roche, Sanofi

Key drugs: Dupixent, Fasenra, Nucala, Tezspire (tezepelumab), Xolair, LABA/ICS FDCs, LABA/LAMA/ICS FDCs